This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:ibd [02.17.2019] – [Inflammatory bowel disease (Crohn's disease and ulcerative colitis)] sallieq | home:diseases:ibd [03.21.2019] – [Research] sallieq | ||
---|---|---|---|
Line 181: | Line 181: | ||
===== Research ===== | ===== Research ===== | ||
+ | |||
+ | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
+ | |||
+ | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. | ||
Development, | Development, | ||
Line 194: | Line 198: | ||
' | ' | ||
- | [[https://www.sciencemag.org/news/2018/11/do-gut-bacteria-make-second-home-our-brains|Roberts doesn’t know how these bacteria could have gotten into the brain. They may have crossed from blood vessels, traveling up nerves from the gut, or even come in through the nose]] | + | Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. |
+ | |||
+ | Butyric acid in functional constipation | ||
+ | |||
+ | Butyric acid in irritable bowel syndrome | ||
| | ||
+ | | ||
+ | |||
+ | [[https:// | ||
+ | | ||
+ | [[https:// | ||
+ | |||
+ | |||
+ | [{{: | ||
===== Patient interviews | ===== Patient interviews | ||